Scholarlink

The field of cardio-oncology serves as a venue for both exploration and risk mitigation of cardiovascular outcomes in this space. While the body of evidence for anticancer therapies continues to grow, the cardiovascular toxicities associated with these treatments have also become more apparent. Recent literature suggests that sex and racial disparities exist in risk for development of cardiovascular disease and mortality, both during and after treatment with anticancer therapies. This work aims to (1) elucidate the current state of cardio-oncology in regards to these disparities; (2) review current data on women and underrepresented minority populations in the treatment of breast cancer, radiotherapy, and targeted or immune-based therapies; (3) recognize both nonbiologic (social determinants of health, clinical trial representation, and environment) and biologic (epigenetic stress, genomic markers, and inflammation pathways) sources of disparate cardiovascular risk and outcomes; and (4) identify further areas for exploration in order to address these disparities.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multilevel Drivers of Disparities in Cardio-Oncology

  • 章节

  • 发表日期：

    2025年

查看全文
  • Megan McCrohan,
  • Tyren Busby,
  • Dionisia Quiroga,
  • Mary Branch,
  • Arnethea L. Sutton,
  • Sherry-Ann Brown,
  • Sarju Ganatra,
  • Sanam Ghazi,
  • Onaopepo Kola-Kehinde,
  • Mussammat Ferdousi,
  • Karen P. Williams,
  • Eric D. Miller,
  • Daniel Addison

摘要

The field of cardio-oncology serves as a venue for both exploration and risk mitigation of cardiovascular outcomes in this space. While the body of evidence for anticancer therapies continues to grow, the cardiovascular toxicities associated with these treatments have also become more apparent. Recent literature suggests that sex and racial disparities exist in risk for development of cardiovascular disease and mortality, both during and after treatment with anticancer therapies. This work aims to (1) elucidate the current state of cardio-oncology in regards to these disparities; (2) review current data on women and underrepresented minority populations in the treatment of breast cancer, radiotherapy, and targeted or immune-based therapies; (3) recognize both nonbiologic (social determinants of health, clinical trial representation, and environment) and biologic (epigenetic stress, genomic markers, and inflammation pathways) sources of disparate cardiovascular risk and outcomes; and (4) identify further areas for exploration in order to address these disparities.